Blog
RSS FeedPosted by Michael Wonder on 12 Sep 2019
Batten disease treatment: parents win battle ahead of court date
11 September 2019 - Families of children with a rare degenerative disease have won their fight for funding for NHS ...
Posted by Michael Wonder on 11 Sep 2019
NICE publishes its 600th technology appraisal guidance
12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the ...
Posted by Michael Wonder on 11 Sep 2019
Children with rare inherited condition to benefit from drug through managed access agreement
11 September 2019 - It is estimated that in the UK there are around 30 to 50 children living with the ...
Posted by Michael Wonder on 09 Sep 2019
Subscription model for antibiotic development
6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...
Posted by Michael Wonder on 09 Sep 2019
Will the UK run out of insulin and other vital medicines in a no-deal Brexit?
9 September 2019 - All but the most brazen companies aim to win their customers’ trust. But for businesses supplying ...
Posted by Michael Wonder on 02 Sep 2019
NHS saves more than £700 million on medicines costs
2 September 2019 - The NHS has announced that it has saved more than £700 million from the annual medicines ...
Posted by Michael Wonder on 28 Aug 2019
Who could replace Sir Andrew Dillon at NICE?
28 August 2019 - With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements ...
Posted by Michael Wonder on 28 Aug 2019
Batten disease treatment: parents can take fight to High Court
28 August 2019 - Two sets of parents of children with a rare degenerative disease can take a fight for ...
Posted by Michael Wonder on 25 Aug 2019
Cannabis oil too expensive to prescribe to epileptic children on NHS, advisory body finds
23 August 2019 - A cannabis drug used to treat children with epilepsy is too expensive to prescribe even though ...
Posted by Michael Wonder on 23 Aug 2019
NICE to work with company on addressing issues in appraisals of cannabidiol for treating difficult to control epilepsies
23 August 2019 - NICE has today announced its intention to work with GW Pharma to address the issues highlighted by ...
Posted by Michael Wonder on 22 Aug 2019
Sir Andrew Dillon to stand down as NICE chief executive
22 August 2019 - Sir Andrew Dillon has announced his intention to stand down as NICE chief executive next year. ...
Posted by Michael Wonder on 22 Aug 2019
ABPI position on US trade deal and medicines pricing
21 August 2019 - In response to concerns about the impact a US trade deal would have on medicine pricing, ...
Posted by Michael Wonder on 21 Aug 2019
NICE’s fast-track catapults Skyrizi into market
21 August 2019 - Watchdog also gives direction on comparing rival treatments. ...
Posted by Michael Wonder on 21 Aug 2019
NHS to reimburse Hemlibra
21 August 2019 - NHS England has commissioned Roche and Chugai’s joint haemophilia A drug, Hemlibra (emicizumab), agreeing to fund ...
Posted by Michael Wonder on 20 Aug 2019
NICE’s track record in cancer drugs: the impact of the CDF and interim funding
20 August 2019 - Cancer drugs and the decisions made by the UK’s NICE have been subject to much scrutiny ...